Evidence map›Paper›PMID 31406138›Full record

ArticleScientific reports2019

TGR(mREN2)27 rats develop non-alcoholic fatty liver disease-associated portal hypertension responsive to modulations of Janus-kinase 2 and Mas receptor.

Sabine Klein, Carola-Ellen Kleine, Andrea Pieper, Michaela Granzow, Sebastian Gautsch, Mimoun Himmit, Katharina Kahrmann, Robert Schierwagen, Frank Erhard Uschner, Fernando Magdaleno and 6 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.1field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 10 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 5 institutions in 4 countries.

Sabine KleinDepartment of Internal Medicine I, Goethe University Frankfurt, Frankfurt, Germany.
Carola-Ellen KleineDepartment of Internal Medicine I, University of Bonn, Bonn, Germany.
Andrea PieperHouse for Experimental Therapy, University of Bonn, Bonn, Germany.
Michaela GranzowDepartment of Internal Medicine I, University of Bonn, Bonn, Germany.
Sebastian GautschDepartment of Internal Medicine I, University of Bonn, Bonn, Germany.
Mimoun HimmitDepartment of Internal Medicine I, University of Bonn, Bonn, Germany.
Katharina KahrmannDepartment of Internal Medicine I, University of Bonn, Bonn, Germany.
Robert SchierwagenDepartment of Internal Medicine I, Goethe University Frankfurt, Frankfurt, Germany.ORCID http://orcid.org/0000-0002-2195-3666
Frank Erhard UschnerDepartment of Internal Medicine I, Goethe University Frankfurt, Frankfurt, Germany.
Fernando MagdalenoDepartment of Internal Medicine I, University of Bonn, Bonn, Germany.ORCID http://orcid.org/0000-0002-4121-6743
Maria Eleni NaoumInstitute for Bioengineering of Catalonia, Barcelona, Spain.
Glen KristiansenInstitute of Pathology, University of Bonn, Bonn, Germany.
Thomas WaltherDepartment of Pharmacology and Therapeutics, University College Cork, Cork, Ireland.
Michael BaderBerlin Institute of Health (BIH), Berlin, Germany.
Tilman SauerbruchDepartment of Internal Medicine I, University of Bonn, Bonn, Germany.
Jonel TrebickaDepartment of Internal Medicine I, Goethe University Frankfurt, Frankfurt, Germany. jonel.trebicka@ukbonn.de.ORCID http://orcid.org/0000-0002-7028-3881
University of Bonn · DEGoethe University Frankfurt · DEInstitute for Bioengineering of Catalonia · ESMax Delbrück Center · DEUniversity College Cork · IE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Prevalence of non-alcoholic fatty liver disease (NAFLD) is increasing. Resulting fibrosis and portal hypertension, as a possible secondary event, may necessitate treatment. Overexpression of mouse renin in the transgenic rat model, TGR(mREN2)27, leads to spontaneous development of NAFLD. Therefore, we used TGR(mREN2)27 rats as a model of NAFLD where we hypothesized increased susceptibility and investigated fibrosis and portal hypertension and associated pathways. 12-week old TGR(mREN2)27 rats received either cholestatic (BDL) or toxic injury (CCl

Indexed as

AnimalsHypertension, PortalJanus Kinase 2Non-alcoholic Fatty Liver DiseaseProto-Oncogene MasProto-Oncogene ProteinsRatsRats, TransgenicReceptors, G-Protein-CoupledReninRNA, MessengerJak2 protein, ratJanus Kinase 2Proto-Oncogene MasProto-Oncogene ProteinsReceptors, G-Protein-CoupledReninRNA, Messenger

Identifiers

PMID31406138
PMCPMC6690919
OpenAlexW2968206161

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.